custom antibody services Market

The custom antibody services market size is expected to grow from US$ 590.33 million in 2023 to US$ 1,216.35 million by 2031; it is projected to register a CAGR of 9.5% during 2023-2031. The increasing prevalence of chronic diseases and rising approvals of biosimilars are noteworthy factors contributing to the expansion of the custom antibody services market size. However, the high costs and complexities associated with antibody production using transgenic animals hinders the custom antibody services market growth.

Recombinant antibody engineering has a wide scope of potential for drug developers and researchers to create specific molecules with specific attributes ideally suited for treating specific diseases. Several drug developers are already using AI technologies in the prediction and analysis of potential therapeutics from antibody sequences, using algorithms to assess their potential before production has commenced. For instance, Foundation Medicine develops, manufactures, and sells genomic profiling assays on the basis of next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas that can be utilized to match patients with targeted therapies, immunotherapies, and clinical trial options. Such companies also partner with the biopharma industry to help discover, develop, and distribute the next breakthrough treatments for patients. The Medicines Discovery Catapult is testing (on a computer) an in-silico pipeline for identifying new molecules for cancer treatment; for example, applying AI to find new disease drivers as well as candidate drugs for lung cancer. Thus, technological advancements using recombinant antibodies are expected to bring new trends into the custom antibody services market in the coming years.

Application -Based Insights

Based on application, the custom antibody services market is segmented into immunohistochemistry, western blot and IP, ELISA, fluorescence-activated cell sorting, mass spectrometry, and others. The ELISA segment held the largest custom antibody services market share in 2023. Enzyme-linked immunosorbent assay (ELISA) is a test that detects and measures antibodies in an individual's blood. It can be used to determine if a person has antibodies related to certain infectious conditions. A few examples of these infections include bacterial, viral, or fungal infections. ELISA is an immunological assay that helps measure antibodies, antigens, proteins, and glycoproteins in biological samples. A few examples include the diagnosis of HIV infection, pregnancy tests, and measurement of cytokines or soluble receptors in cell supernatant or serum. Monoclonal antibodies are produced by a single B-cell clone and target a single epitope on an antigen. They can be used in medical diagnoses, including ELISA tests, which are quick and reliable. In addition to qualitative indications of the presence or absence of an analyte in a sample, ELISAs can provide a measurement of absolute levels of protein or peptide in a large number of samples, giving it a strong advantage over related techniques such as immunohistochemistry (IHC), immunocytochemistry (ICC), or western blot.

The Centers for Disease Control and Prevention, the International Diabetes Federation, and American Cancer Society are among the primary and secondary sources referred to while preparing the custom antibody services market report.